BL-B01D1临床开展情况（截至2024年年报）-行业数据

BL-B01D1临床开展情况（截至2024年年报）

公司首次覆盖报告 BL-B01D1是公司全力推进的重磅 EGFR/HER3 ADC药物，有望于 2025H2向CDE递交 NDA。BL-B01D1全球首个的靶向 EGFR×HER3的双抗 ADC药物，目前在中国 BL-B01D1 单药治疗三线鼻咽癌、二线食管鳞癌已进入 III 期临床并有望于2025H2 递交 NDA；治疗 EGFR 野生型非小细胞肺癌、EGFRmut 非小细胞肺癌、

行业数据

下载图片

原图定位

同报告图片

/ 4

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